AllSci News
Superluminal raises USD 60m Series B to take rare obesity drug into Phase I
Boston-based Superluminal Medicines has closed an oversubscribed USD 60 million Series B financing round to advance its lead small-molecule melanocortin-4...
Peking University engineers proteins that switch on in nitric oxide-rich tissues
A method for building proteins that activate only in the presence of nitric oxide (NO) — a signaling molecule produced at elevated levels at sites of...
ENA expands antiviral nasal spray INNA-051 into asthma patients with grant backing
Australia-based ENA Respiratory has received AUD 2.98 million (USD 1.9 million) from Biointelect Venturer to fund the first study of its INNA-051 antiviral...
Soufflé joins DUX4 race in FSHD with muscle-targeted siRNA conjugate
Massachusetts-based Soufflé Therapeutics, Inc. has registered a Phase I/II clinical trial of SFL-0821, an antibody-siRNA conjugate designed to silence DUX4...
China approves Milestone/Everest's Cardamyst nasal spray for acute PSVT
China's National Medical Products Administration (NMPA) has approved Cardamyst (etripamil) nasal spray for the treatment of paroxysmal supraventricular...
FDA approves Zanvastro as first disease-modifying treatment for Alexander disease
The US FDA has approved Zanvastro (zilganersen), an antisense oligonucleotide (ASO) targeting glial fibrillary acidic protein (GFAP) mRNA, for the treatment...
Cipla joins Keytruda biosimilar race with Qilu deal
India-based Cipla Limited (BSE: 500087; NSE: CIPLA) has secured exclusive US commercialization rights for QL2107, a biosimilar to pembrolizumab (Keytruda),...
Thryv expands SGK1 platform into neurodegeneration with Spanish academic license
Montréal-based Thryv Therapeutics Inc. has licensed an exclusive, worldwide patent and know-how rights to a structurally distinct class of SGK1 inhibitors...
AbbVie closes USD 10.9b Apogee purchase for IL-13 zumilokibart
AbbVie (NYSE: ABBV) completed its acquisition of Apogee Therapeutics on September 3, 2026, paying USD 135.11 per share in cash for a total equity value of...
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal
Medicus Pharma Ltd. (Nasdaq: MDCX) has licensed worldwide rights to Pfizer's PF-08046031 (CD228V), an early clinical-stage antibody-drug conjugate (ADC)...
China approves two homegrown long-acting RSV antibodies for infants
China's National Medical Products Administration (NMPA) has approved two domestically developed long-acting monoclonal antibodies for the prevention of...
AbbVie’s monthly BCMAxCD3 bispecific clears Phase III hurdle
AbbVie (NYSE: ABBV) has reported that etentamig, its investigational BCMA × CD3 bispecific T-cell engager (TCE), met both dual primary endpoints in the...
Hengrui files Kailera-partnered oral GLP-1 for China approval in obesity and diabetes
China's drug regulator has accepted a marketing authorization application for HRS-7535 tablets, an oral small-molecule glucagon-like peptide-1 receptor...
ARPA-H backs USD 125m push for distributed RNA manufacturing
The Advanced Research Projects Agency for Health (ARPA-H) has selected five teams to receive contract awards totaling up to USD 125 million under its...
Servier secures option to Luxna's XNA chemistry platform for neurological ASO programs
Servier has expanded its research collaboration focused on Luxna Biotech Co., Ltd's XNAs Technology platform. The France-based pharmaceutical giant has...
The AllSci Brief
Free, systematic R&D and deal news. Daily.